Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious OutperformanceFind Stocks Now

Eckert & Ziegler BEBIG SA (EZBG)

Brussels
Currency in EUR
Disclaimer
16.300
0.000(0.00%)
Closed
EZBG Scorecard
Fair Value
Unlock Value
Day's Range
16.20016.300
52 wk Range
0.00016.300
Bid/Ask
16.30 / 16.60
Prev. Close
16.5
Open
16.2
Day's Range
16.2-16.3
52 wk Range
0-0
Volume
0
Average Vol. (3m)
454
1-Year Change
0%
Shares Outstanding
2,332,500
Fair Value
Unlock
Dividends Payment Streak
Unlock
Technical
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Daily
Weekly
Monthly
More
How do you feel today about EZBG?
Vote to see community's results!
or

Eckert & Ziegler BEBIG SA Company Profile

As of February 18, 2019, Eckert & Ziegler BEBIG S.A. was acquired by Eckert & Ziegler Strahlen- und Medizintechnik AG. Eckert & Ziegler BEBIG S.A. through its subsidiaries, develops, manufactures, and sells radiation equipment and related products based on isotope technology. It offers IsoSeed for the treatment of prostate cancer; Mick TP/TPV Applicator System, a brachytherapy implantation technique that allows for seed placement adjustments during implant to adapt changes of prostate size and position; IsoCord, a seed chain that provides radiation protection; IsoStrand, a seed chain that consists of 10 IsoSeeds with 1.0 cm center-to-center spacing for protection against radiation; and needles for LDR brachytherapy. The company also offers IsoSeed I25.S17plus loose seeds for brain tumor treatment; SagiNova and MultiSource HDR (high dose rate) afterloader systems for the HDR brachytherapy applications; SagiPlan software for HDR treatment plans; and Cobalt-60 for various HDR brachytherapy treatments. In addition, it offers gynecological and rectal HDR applicators and accessories; CT/MR contour prostate template sets; tongue and mouth, and nasopharynx applicator sets; breast bridge sets; esophagus applicator and bronchus intraluminal sets; Harrison-Anderson-Mick applicators; and Valencia applicator sets. Further, the company provides products for the temporary brachytherapy of eye cancers, including Ru-106 eye applicators for the treatment of uveal melanoma and retinoblastoma; and I-125 ophthalmic seeds for use in COMS eye applicators to treat eye tumors, such as uveal melanomas and retinoblastomas, as well as offers radiotherapy accessories. It markets and sells its products to oncologists, radiologists, urologists, and medical physicists through a network of distributors and agents worldwide. The company was formerly known as International Brachytherapy s.a. and changed its name to Eckert & Ziegler BEBIG S.A. in June 2011. The company was founded in 1996 and is headquartered in Seneffe, Belgium.

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.